Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cells (National Medical Research Center for Hematology)
- Development stage
- Unknown
- Lead developer
- National Research Center for Hematology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of multipotent mesenchymal stromal cells (MMSCs) derived from the bone marrow of allogeneic hematopoietic stem cell donors. Developed by the National Research Center for Hematology in Russia, the therapy is intended for the prophylaxis and treatment of acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic stem cell transplantation for conditions such as acute leukemia, aplastic anemia, or multiple myeloma. The cells are cultured in alpha-MEM supplemented with human platelet lysate and administered via intravenous infusion. The mechanism of action involves potent immunomodulation, primarily through the suppression of T-cell activation and the reduction of inflammatory cytokine production, thereby mitigating the immune-mediated tissue damage characteristic of GVHD.
- Other names
- multipotent mesenchymal stromal cellsbone marrow mesenchymal stem cellsmesenchymal stromal cellsMSCs
Beyond the preview
Go deeper on mesenchymal stem cells (National Medical Research Center for Hematology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cells (National Medical Research Center for Hematology).